Figure 1.

Performance of AFP, β-HCG, miR-371a-3p and RASSF1A_M in detecting testicular germ cell tumor patients at time of diagnosis. Results are presented color-coded, referring to all testicular germ cell tumor patients (n = 98); all seminomas (n = 21); all non-seminomas (including teratomas, n = 77); all teratomas (n = 9); and all GCNIS-only patients (n = 5). Notice that both miR-371a-3p and RASSF1A_M show better detection performance than the combination of both AFP and β-HCG, and that combination of the former two biomarkers results in 100% sensitivity for detecting TGCT patients, including those with teratoma and those with GCNIS-only. Abbreviations: AFP—alpha fetoprotein; β-HCG—human chorionic gonadotropin subunit β; GCNIS—germ cell neoplasia in situ; RASSF1A_M—hypermethylated RASSF1A; TE—teratoma.